stockrow
Monday 9 November 2026
Export BJDX’s income statement to Excel — free account
Bluejay Diagnostics, Inc.
BJDXBluejay Diagnostics, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $249,000.00.
- EPS
- +80.1%
- Free cash flow
- +20.1%
Quarter to June 2026, against a year earlier
2.35
0.16
+7.31%
Follow BJDX
Alert me
Bluejay Diagnostics, Inc. (BJDX) P/E ratio
Bluejay Diagnostics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2022 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NUVOQ Holdco Nuvo Group D.G Ltd. compare | n/m |
| ICCM IceCure Medical Ltd. compare | n/m |
| VVOS Vivos Therapeutics, Inc. compare | n/m |
| BJDX Bluejay Diagnostics, Inc. | n/m |
| CODX Co-Diagnostics, Inc. compare | n/m |
| AMIX Autonomix Medical, Inc. compare | n/m |
| AIDX 20/20 Biolabs Inc. compare | n/m |
| IVF INVO Fertility, Inc compare | n/m |
| NUWE Nuwellis, Inc. compare | n/m |
| Medical Devices industry median | 24.9× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)